|
Jul 21
|
ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
|
|
Jul 18
|
MHRA approves needle-free adrenaline nasal spray for anaphylaxis
|
|
Jul 18
|
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
|
|
Jul 18
|
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
|
|
Jun 16
|
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
|
|
May 8
|
ITULATEK® approved for treatment of children and adolescents in Canada
|
|
May 6
|
Three-month interim report (Q1) 2025 (unaudited)
|
|
Feb 12
|
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025
|
|
Oct 9
|
Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook
|
|
Oct 7
|
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
|
|
Jun 21
|
ALK upgrades its full-year revenue and earnings outlook
|
|
Jun 21
|
ALK provides update on regulatory process for the house dust mite allergy tablet in China
|
|
Jan 4
|
ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy
|
|
Dec 20
|
ALK – Financial calendar for the 2024 financial year
|